Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial

Journal of Clinical Lipidology

Volumn 10, Issue 1, 2016, Pages 181-191.e2

  Bays, Harold E ^a   Hallén, Jonas ^b   Vige, Runar ^b   Fraser, David ^b   Zhou, Rong ^c   Hustvedt, Svein Olaf ^b   Orloff, David G ^c   Kastelein, John J P ^d  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Pronova BioPharma AS   (Norway)

^c Medpace Inc ^*  (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Apolipoprotein C III; Hypertriglyceridemia; Icosabutate; Remnants; Triglycerides

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSABUTATE; LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; OMEGA 3 FATTY ACID;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BACKACHE; BLEPHAROSPASM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERUCTATION; FATIGUE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SPRAIN; URINARY TRACT INFECTION; ADOLESCENT; BLOOD; CHEMISTRY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84958903756     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.10.012     Document Type: Article

References (28)

1. H.E. Bays, P.H. Jones, W.V. Brown, and T.A. Jacobson National Lipid Association Annual Summary of Clinical Lipidology 2015 J Clin Lipidol 8 2014 S1 S36
2. H.E. Bays, P.P. Toth, P.M. Kris-Etherton, and et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association J Clin Lipidol 7 2013 304 383
3. M. Miller, N.J. Stone, C. Ballantyne, and et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
4. T.A. Jacobson, M.K. Ito, K.C. Maki, and et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary J Clin Lipidol 8 2014 473 488
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 2002. (Accessed 25, 106, at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=12485966 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=12485966
6. N. Sarwar, J. Danesh, G. Eiriksdottir, and et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458
7. FDA. Omtryg Prescribing Inf. 2014. Available at: https://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204977s000lbl.pdf.
8. W.S. Harris, H.N. Ginsberg, N. Arunakul, and et al. Safety and efficacy of Omacor in severe hypertriglyceridemia J Cardiovasc Risk 4 1997 385 391
9. J.J. Kastelein, K.C. Maki, A. Susekov, and et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial J Clin Lipidol 8 2014 94 106
10. H.E. Bays, C.M. Ballantyne, J.J. Kastelein, J.L. Isaacsohn, R.A. Braeckman, and P.N. Soni Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial) Am J Cardiol 108 2011 682 690
11. Chowdhury IN. Clinical review, NDA 202057, Vascepa/Icosapent Ethyl. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/202057Orig1s000MedR.pdf.
12. M.H. Davidson, E.A. Stein, H.E. Bays, and et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 1354 1367
13. L.N. Larsen, J. Bremer, S. Flock, and L. Skattebol Alpha- and beta- alkyl-substituted eicosapentaenoic acids: incorporation into phospholipids and effects on prostaglandin H synthase and 5-lipoxygenase Biochem Pharmacol 55 1998 405 411
14. S. Skrede, H.N. Sorensen, L.N. Larsen, and et al. Thia fatty acids, metabolism and metabolic effects Biochim Biophys Acta 1344 1997 115 131
15. D.A. Fraser, T. Skjaeret, Y. Qin, and et al. Abstract 18507: Icosabutate, a novel structurally enhanced fatty-acid increases hepatic uptake of cholesterol and triglycerides in conjunction with increased hepatic LDL receptor expression Circulation 130 2014 A18507
16. Y. Qin, J. Hallén, T. Skjæret, and et al. Abstract 11889: Phase Ib study of icosabutate, a novel structurally enhanced fatty acid, in subjects with hypercholesterolemia Circulation 130 2014 A11889
17. H. Bays Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids Am J Cardiol 98 2006 71i 76i
18. D.J. Rader, R.L. Dunbar, K.C. Maki, T.A. Jacobson, D. Kling, and M.H. Davidson Apolipoprotein C-III is significantly reduced by prescription omega-3 free fatty acids (Epanova) in patients with severe hypertriglyceridemia and changes correlate with increases in LDL-C: a sub-analysis of the EVOLVE trial Circulation 126 2012 A19030
19. C.M. Ballantyne, H.E. Bays, R.A. Braeckman, and et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies J Clin Lipidol 8 2014 313 314
20. D. Gaudet, D. Brisson, K. Tremblay, and et al. Targeting APOC3 in the familial chylomicronemia syndrome N Engl J Med 371 2014 2200 2206
21. M.J. Graham, R.G. Lee, T.A. Bell, and et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans Circ Res 112 2013 1479 1490
22. C. Zheng, C. Khoo, J. Furtado, and F.M. Sacks Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype Circulation 121 2010 1722 1734
23. A.B. Jorgensen, R. Frikke-Schmidt, B.G. Nordestgaard, and A. Tybjaerg-Hansen Loss-of-function mutations in APOC3 and risk of ischemic vascular disease N Engl J Med 371 2014 32 41
24. Tg, Hdl Working Group of the Exome Sequencing Project NHL, Blood Institute, J. Crosby, G.M. Peloso, P.L. Auer, D.R. Crosslin, N.O. Stitziel, and et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 2014 22 31
25. J. Liu, C.T. Sempos, R.P. Donahue, J. Dorn, M. Trevisan, and S.M. Grundy Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease Am J Cardiol 98 2006 1363 1368
26. S.M. Boekholdt, B.J. Arsenault, S. Mora, and et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
27. E.M. Balk, A.H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review Atherosclerosis 189 2006 19 30
28. H.E. Bays Safety considerations with omega-3 fatty acid therapy Am J Cardiol 99 2007 35C 43C